{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-010747","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2025-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.825842+00:00","generated_at":"2026-05-27T01:37:00.890310+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Citius Pharma receives permanent J-code J9161 for LYMPHIR, effective April 1, 2025","bullets":["CMS assigned permanent HCPCS J-code J9161 to LYMPHIR (denileukin diftitox-cxdl) for CTCL.","J-code effective April 1, 2025, streamlines billing and reimbursement for providers.","LYMPHIR approved by FDA for relapsed/refractory Stage I-III CTCL after prior systemic therapy.","CEO Leonard Mazur says J-code is critical for patient access and coverage by commercial & government insurers."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-010747","json":"https://secwatch.observer/filing/0001213900-25-010747.json","markdown":"https://secwatch.observer/filing/0001213900-25-010747.md","text":"https://secwatch.observer/filing/0001213900-25-010747.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390025010747/0001213900-25-010747-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390025010747/ea0230159-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T01:37:00.890310+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}